BAX - Baxter International Inc.
| Previous Close | 67.00 |
| Open | 67.02 |
| Bid | 0.00 x 800 |
| Ask | 66.78 x 1300 |
| Day's Range | 66.54 - 67.51 |
| 52 Week Range | 61.05 - 78.38 |
| Volume | 2,796,041 |
| Avg. Volume | 3,915,149 |
| Market Cap | 35.627B |
| Beta (3Y Monthly) | 1.21 |
| PE Ratio (TTM) | 30.67 |
| EPS (TTM) | 2.18 |
| Earnings Date | Jan 31, 2019 |
| Forward Dividend & Yield | 0.76 (1.14%) |
| Ex-Dividend Date | 2018-11-30 |
| 1y Target Est | 74.00 |
- Zacks•20 hours ago
Here's Why You Should Hold Baxter International (BAX) Now
Baxter's (BAX) recent string of developments boost the stock while segmental softness is a concern.
Markit•21 hours agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
Market Realist•21 hours agoHow Medtronic’s Cardiac and Vascular Group Performed
Medtronic’s (MDT) Cardiac & Vascular Group generated revenues of $2.9 billion in the second quarter of fiscal 2019 compared to $2.8 billion in the second quarter of fiscal 2018, reflecting ~3% YoY growth.
Market Realist•3 days agoWill GE’s Healthcare Unit Spin-Off Increase Shareholder Wealth?
Why Has General Electric Stock Struggled in 2018? The Healthcare segment is the fourth-largest contributor to General Electric’s total revenues. As part of the company’s major restructuring plan in June, General Electric intends to spin off the segment and turn it into a standalone entity.
Markit•3 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
- Zacks•4 days ago
Baxter & EFCNI Collaborate to Improve Care for Preterm Born
Baxter's (BAX) latest move is likely to increase the use of Baxter's Numeta G13E triple-chamber PN product.
- Insider Monkey•6 days ago
Hedge Funds Are Still Crazy About Baxter International Inc. (BAX)
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]
GuruFocus.com•7 days agoDan Loeb Sells Baxter International Shares at Strong Gain
Daniel Loeb (Trades, Portfolio), whose fund is posting negative returns this year, reported on Wednesday that he unloaded a portion of one of his highly profitable bets, health care company Baxter International (BAX). Warning! GuruFocus has detected 1 Warning Sign with GOOG. The sale resulted from the "portfolio concentration level" it had reached in the portfolio of his hedge fund, Third Point.
- Business Wire•7 days ago
Baxter Supports New EFCNI Standards in Newborn Care in Raising Awareness of Risks from Malnutrition
Baxter International Inc. (BAX), a global leader in clinical nutrition, is collaborating with the European Foundation for the Care of Newborn Infants (EFCNI) to raise awareness for the new EFCNI standards that address the disparities in newborn care in Europe. EFCNI released the new European Standards of Care for Newborn Health last week.
- Business Wire•8 days ago
Baxter Appoints Patricia Morrison and Amy Wendell to Its Board
Baxter International Inc. (BAX), a leading global medical products company, today announced it has appointed Patricia B. (Patty) Morrison, former Cardinal Health executive vice president and chief information officer, and Amy A. Wendell, former Covidien senior vice president of strategy and business development, to its board of directors.
- Business Wire•10 days ago
Baxter to Present at the 37th Annual J.P. Morgan Healthcare Conference
Baxter International Inc. , a leading global medical products company, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. José E. Almeida, Baxter’s chairman and chief executive officer, is scheduled to present on Monday, January 7, 2019 at 10 a.m.
- Simply Wall St.•13 days ago
Baxter International Inc (NYSE:BAX): Has Recent Earnings Growth Beaten Long-Term Trend?
Today I will examine Baxter International Inc’s (NYSE:BAX) latest earnings update (30 September 2018) and compare these figures against its performance over the past couple of years, in addition to Read More...
Market Realist•15 days agoEdwards Lifesciences Stock: Analysts Remain Bullish
In November, among the 22 analysts covering Edwards Lifesciences (EW), 13 recommended a “buy” or higher rating, seven recommended a “hold” rating, and two recommended a “sell” or lower rating. The mean rating for Edwards Lifesciences stock is 2.32 with a target price of $161.53, which implies an upside potential of 4.5% over Edwards Lifesciences’ closing price of $154.52 on November 27.
GuruFocus.com•15 days agoMS Global Franchise Fund's Top 5 Buys in 3rd Quarter
Fund adds to two existing positions and introduces three new holdings
Market Realist•24 days agoGE’s Healthcare Unit Spin-Off to Maximize Shareholders’ Wealth
General Electric’s (GE) Healthcare segment, which offers medical imaging and information technologies, biopharmaceutical manufacturing technologies, and patient monitoring systems, is one of the company’s better-performing units and is the fourth-largest contributor to its total revenue.
Market Realist•25 days agoBaxter International: Analysts Remain Bullish on the Stock
In November, among the 17 analysts covering Baxter International (BAX), ten analysts recommended a “buy” or a higher rating, five recommended a “hold” rating, and three recommended a “sell” rating. The mean rating for Baxter International stock is 2.29 with a target price of $73.27, which implies an upside potential of 11.3% over Baxter International’s closing price of $65.83 on November 15.
- Market Realist•28 days ago
Analyzing Baxter International’s Operational Performance
Baxter International’s (BAX) cost of sales decreased from $1.58 billion in the third quarter of 2017 to $1.53 billion in the third quarter. The company’s gross profit increased from $1.13 billion in the third quarter of 2017 to $1.24 billion in the third quarter due to the favorable product mix and manufacturing efficiencies.
- Market Realist•28 days ago
What Baxter International’s Bottom-Line Trend Indicates
Baxter International’s (BAX) net interest expense decreased from $14.0 million in the third quarter of 2017 to $11.0 million in the third quarter. The company’s net other income increased from $4.0 million in the third quarter of 2017 to $32.0 million in the third quarter. While the company incurred an income tax expense of $42.0 million in the third quarter of 2017, it received an income tax benefit of $138.0 million in the third quarter.
Market Realist•28 days agoBaxter International: Why Investors Are Interested
Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018. In this series, we’ll discuss Baxter International’s financials, analysts’ views on the stock, valuation metrics, and geographic performance. The company’s business units include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery, and acute therapies.
- Zacks•29 days ago
Baxter (BAX) Launches Peri-Strips & Tisseel Prima, Shares Up
Baxter's (BAX) diversified surgical portfolio lends it a competitive edge in the MedTech space.
- Business Wire•last month
Baxter Unveils New Products at the ASMBS – Obesity Week Meeting to Help Surgeons Overcome Challenges During Bariatric Surgery
Baxter International Inc. (BAX), a global leader in advancing surgical innovation, revealed its Peri-Strips Dry with Veritas (PSDV) Circular Staple Line Reinforcement with Secure Grip technology, the latest evolution in a product portfolio that has more than 20 years of proven clinical use in surgical buttressing and soft tissue repair. PSDV Circular is being showcased alongside the company’s comprehensive Advanced Surgery portfolio at the 2018 American Society for Metabolic and Bariatric Society (ASMBS) – Obesity Week meeting this week.
Market Realist•last monthInside General Electric’s Healthcare Business Unit Spin-Off Plan
As part of its major restructuring plan, General Electric (GE) intends to spin off its Healthcare segment and turn it into a standalone entity. The company has planned the spin-off in a manner that maximizes shareholder wealth.
- MarketWatch•last month
Baxter board approves $2 billion increase to share buyback authorization
Baxter International Inc. said Tuesday its board has approved a $2 billion increase to its share buyback authorization, bringing the total available to $3.4 billion. The medical products company's shares were up 1.1% premarket, but have fallen about 5% in 2018, while the S&P 500 has gained 2%.
- Business Wire•last month
Baxter Declares Quarterly Dividend and Announces Expanded Share Repurchase Authorization
Baxter International Inc. (BAX), a leading global medical products company, announced today a quarterly cash dividend and an expanded authorization for its share repurchase program. Baxter’s Board of Directors has also approved a $2.0 billion increase in authorization for the company’s existing share repurchase plan. Based on these actions, the share repurchase plan has approximately $3.4 billion of repurchase authority available as of the date hereof to make repurchases pursuant to new or existing Rule 10b5-1 plans or otherwise.
- Business Wire•last month
Baxter Highlights Data at ISPOR Europe 2018 on Clinical and Economic Benefits When Addressing Malnutrition, Intraoperative Bleeding
Studies examine cancer-related malnutrition and nutrition management in pre-term babies, as well as the use of hemostats in specific pancreatic and spinal surgeries
